Cultivated Meat's Scale Problem After the Reset
Israel made the world's first cultivated-meat regulatory history — and watched its best-funded cultivated-meat company shut down. Both facts are the story.
Cultivated meat — real animal protein grown from cells in a bioreactor, without slaughter — is the most scientifically ambitious corner of the protein transition, and Israel has been at its frontier. In early 2024, Israel became the first country in the world to grant regulatory approval for cultivated beef, to Aleph Farms. Less than two years later, in December 2025, Believer Meats — formerly Future Meat, once the best-funded cultivated-meat company in the country — ceased operations. The distance between those two events is the entire problem with cultivated meat: the science works; the economics, so far, do not.
The cost curve versus the commercialization gap
The central obstacle has always been cost, and the gap between laboratory cost and commercial cost is where companies die. Growing animal cells at scale requires expensive culture media and large, sterile bioreactors, and for years the math was hopeless — early cultivated product cost orders of magnitude more than farmed meat. The progress has been real: Aleph Farms reports cutting production costs by roughly 97 percent since 2020, and a Hebrew University team led by Professor Yaakov Nahmias — who founded Believer Meats — published a continuous-manufacturing method in Nature Food using tangential-flow filtration that drove costs toward roughly five dollars a pound, with animal-free media at well under a dollar a liter. But a cost achieved in a research line is not a cost achieved on a balance sheet. The frontier is no longer whether costs can fall in principle, but whether a company can hold them down across an industrial-scale plant, at volume, while still covering capital and overhead — the leap from a promising unit cost to a profitable production line.
Approval is not the same as scale
Israel's regulatory firsts created a misleading sense of arrival. Aleph Farms won the world's first cultivated-beef approval; Believer Meats secured an FDA clearance for cultivated chicken in 2025 — shortly before it folded. Regulatory approval proves a product is safe to sell. It does not prove it can be made at a price anyone will pay, in volumes that matter. Believer's failure, coming after both heavy funding and a regulatory green light, is the cautionary case: you can clear every gate and still run out of road if the unit economics do not close.
Who's still in, and how
Aleph Farms, the survivor, has explicitly adjusted to the new climate. It raised a comparatively modest 29-million-dollar round in 2025 — openly acknowledging the sector-wide correction and the repriced terms that came with it — acquired a larger facility in Modi'in, simplified its whole-cut process to remove a production step, and now targets cost parity with premium beef by 2028. The strategy is capital efficiency over land-grab: scale a pilot toward profitability rather than burn through a war chest chasing volume the market is not ready for. (For the regulatory-landmark angle, see Israeli Cultivated Meat After the Aleph Approval.)
The honest verdict
Cultivated meat is the highest-risk layer of Israel's protein bet, and the one most likely to disappoint on the timelines its boosters once promised. But it is also the only technology that produces actual animal meat without animals, which is why serious capital and a serious government have not walked away entirely. The reset killed the weakest players and forced the survivors into discipline. Whether that discipline reaches price parity before patience runs out is the open question — and on current evidence, it is genuinely open.
Part of Olam's Agriculture & Food Tech coverage. See the pillar: Why Israel Bet the Farm on the Protein Transition.
